Comparative Pharmacology
Head-to-head clinical analysis: CARBINOXAMINE MALEATE versus LIVOSTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBINOXAMINE MALEATE versus LIVOSTIN.
CARBINOXAMINE MALEATE vs LIVOSTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbinoxamine maleate is a first-generation antihistamine that competitively inhibits histamine at H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
Levocabastine is a selective histamine H1-receptor antagonist, inhibiting histamine release from mast cells and basophils.
Adults: 4-8 mg orally every 6-8 hours as needed. Maximum: 24 mg/day.
1 drop (0.05% ophthalmic solution) in affected eye twice daily, up to 4 times daily if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment, requiring dose adjustment in significant liver disease.
Terminal elimination half-life in adults: 35-40 hours; clinical context: supports once-daily dosing, with steady-state reached after approximately 7 days
Primarily renal excretion of metabolites and unchanged drug; ~60-70% of a dose is excreted in urine within 48 hours, with less than 5% as unchanged drug. Biliary/fecal elimination accounts for a minor fraction (<10%).
Renal excretion as unchanged drug and metabolites: ~70% (48% unchanged, 9% as levocabastine glucuronide, 13% as other metabolites); fecal excretion: ~20%
Category C
Category C
Antihistamine
Antihistamine